摘要
选取2013-2019年上海、深圳证券交易所中医药医疗类上市公司为研究样本,采用逻辑回归和多元线性回归分析方法,分别研究在不同创新环境约束下,政府创新研发补贴对医药医疗企业创新研发投入和创新绩效的影响,以及此种影响在不同区域中、不同企业性质情形下表现出的差异。研究结论为政府合理制定创新补贴政策和医药医疗企业提高创新能力提供了决策依据。
This paper selects the medical and health listed companies on the Shanghai and Shenzhen Stock Exchanges from 2013 to 2019 as the research samples,and uses logistic regression and multiple linear regression analysis methods were employed to study the impact of government innovation R&D subsidies on the innovation R&D of medical and health companies under different regulatory constraints,as well as the differences of this kind of influence in different regions and under different enterprise nature situations The research conclusions provide a decision-making basis for the government to rationally formulate innovation subsidy policies and medical and health enterprises to improve their innovation capabilities.
作者
徐骁枫
曹思依
孟晓非
XU Xiaofeng;CAO Siyi;MENG Xiaofei(East China University of Political Science and Law,School of International Finance and Law,Shanghai 200042,China;Shanghai Intellectual Property Court,Shanghai 201203,China)
出处
《同济大学学报(自然科学版)》
EI
CAS
CSCD
北大核心
2021年第4期606-616,共11页
Journal of Tongji University:Natural Science
基金
国家自然科学基金(71974144)
国家社科基金重大项目(17ZDA140)
国家社科青年基金(19CFX052)。
关键词
政府补贴
医药医疗企业
创新研发投入
创新绩效
内外部规制
government subsidies
medical and health enterprises
innovation R&D investment
innovation performance
internal and external regulations